Diabetes: A Disease of Epidemic Proportions

What Is Diabetes?

Occurs when the body has insufficient insulin production or is unable to respond to its effects

People with type-2 diabetes can remain undiagnosed for many years, unaware of the long-term damage being caused

This can lead to a build-up of glucose in the blood [hyperglycaemia]

Significant unmet needs exist as many patients remain uncontrolled on their current treatment regimen

Type 2 diabetes is the most commonly diagnosed form of diabetes

If untreated, diabetes can lead to serious complications & early death

What Is Diabetes?

Occurs when the body has insufficient insulin production or is unable to respond to its effects

People with type-2 diabetes can remain undiagnosed for many years, unaware of the long-term damage being caused

This can lead to a build-up of glucose in the blood [hyperglycaemia]

Significant unmet needs exist as many patients remain uncontrolled on their current treatment regimen

Type 2 diabetes is the most commonly diagnosed form of diabetes

If untreated, diabetes can lead to serious complications & early death

The Global Diabetes Burden

Incidence of type 2 diabetes is increasing across the globe

Diabetes is projected to affect up to 629 million people by 2045

Demand is rising for treatments that meet individual patient needs

79% of people with diabetes live in low and middle income countries

Type 2 diabetes accounts for around 90% of all diagnosed cases of diabetes

30-80% of people with diabetes remain undiagnosed

AstraZeneca & Diabetes

Seeking to positively impact the lives of patients to help reduce the disease burden and its complications

First company to offer products in all three of the newest, fastest-growing classes of type 2 diabetes treatments:
- SGLT2 inhibitors
- GLP-1 receptor agonists
- DPP-4 inhibitors

Focused on advancing the treatment paradigm to use combination therapies to help more patients achieve their treatment goals

Committed to:

- Ushering in a new era of innovative diabetes care
- Pursuing scientific excellence to address patients’ unmet needs
- Investing in R&D that may help discover novel treatment pathways
- Offering individualised approaches to care


For media use - please obtain local nominated signatory approval before use